| Byetta (exenatide) / AstraZeneca |
2007-001221-10: Postconditioning used for the limitation of infarct size in patients with ST-elevation myocardial infarction (POSTCON). |
|
|
| Ongoing | 4 | 200 | Europe | Solution for injection, byetta | Rigshospitalet, University of Copenhagen | Patients with ST-segment elevation myocardial infarction (STEMI) are routinely treated with primary PCI (pPCI) as a world wide standard. Glucagon like peptide (GLP1) is a genuine hormone created in the gut and with well characterized receptors in heart muscle. Previous studies have proven it to be safe in human and intravenous administration for 72 hours have shown it to reduce infarct size in pPCI. | | | | |
ChiCTR-TNC-10000874: Effects of Exendin-4(GLP-1 receptor activator) on pancreatic B cell function and serum inflammatin factor in fat type 2 diabetes mellitus. |
|
|
| Completed | 4 | 10 | | Exendin-4 GLP-1 receptor activator | Shengjing Hospital of China Medical University; Level of the institution：, Shengjing Hospital of China Medical University | diabetes mellitus | | | | |
ChiCTR-TRC-10000879: Comparison of glycaemic control and beta-cell function among newly diagnosed type 2 diabetic patients treated with exenatide, insulin or rosiglitazone: a multicentre randomized parallel-group trial |
|
|
| Completed | 4 | 414 | | Exenatide injection (Byetta) ;Premixed insulin analog (Humalog Mix 25) ;Pioglitazone (Ruitong) | The Third Affiliated Hospital of Sun Yat-Sen University; Peking University People's Hospital, Eli Lilly, 5010 Program of Sun Yat-Sen University, Ministry of Health | Type 2 diabetes | | | | |
ChiCTR-IPC-15006339: Observation of the effect and safety of exenatide on hepatic biomarkers in elderly patients with type 2 diabetes complicated nonalcoholic fatty liver disease |
|
|
| Not yet recruiting | 4 | 100 | | Exenatide was initiated at 5 mcg twice daily while stopping their pre-study oral hypoglycemic drugs or taking them at reduced dose, titrated to 10 mcg twice daily after one month ;Glargine was started with 0.1IU/kg once-daily at bedtime while continuing their pre-study oral hypoglycemic drugs, and titrated with glucose levels | Metabolic Disease Hospital of Tianjin Medical University; Metabolic Disease Hospital of Tianjin Medical University, The patients will pay for the costs of the drugs and tests demanded by this clinical trial. | type 2 diabetes complicated nonalcoholic fatty liver disease | | | | |
2008-008367-95: Effect of exenatid on microcirculation in patients with type 2 diabetes mellitus and coronary artery disease |
|
|
| Ongoing | 4 | 60 | Europe | Byetta, Byetta, Byetta, Byetta | Karolinska Institutet, Inst för kliniska vetenskaper, Danderyds sjukhus | Patients with type 2 diabetes and coronary artery disease. | | | | |
2009-011158-17: Additional treatment to primary PCI: effects of ischemic postconditioning and Exenatide. |
|
|
| Ongoing | 4 | 280 | Europe | exenatide, Byetta, Byetta | Erasmus MC | Patients with a large myocardial infarction | | | | |
2008-008141-37: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study |
|
|
| Ongoing | 4 | 10 | Europe | exenatide, Byetta, Byetta | Sherwood Forest Hospitals Foundation Trust | sleepiness and lethargy among obese patients with diabetes | | | | |
| Ongoing | 4 | 20 | Europe | Victoza, Byetta, Victoza, Byetta, Victoza, Byetta | CUB - Hôpital Erasme, Friedreich's Ataxia Research Alliance | Friedreich\'s Ataxia | | | | |
ChiCTR-IPR-15006298: Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients: the second year extended follow-up study |
|
|
| Recruiting | 4 | 118 | | exenatide group ;Diet+movement | The first afilliated hospital of Xiamen University; The First afilliated Hospital of Xiamen University, The first afilliated hospital of Xiamen university | diabetes | | | | |
ChiCTR-OPC-16008152: Effect of glucagon like peptide -1 analogues of obese type 2 diabetic patients with abdominal fat |
|
|
| Completed | 4 | 36 | | Byetta treatment ;Acarbose treatment | Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University; Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University, Provincial innovation team discipline construction project | Obesity, diabetes | | | | |
ChiCTR-IPR-15006008: Effect of Exenatide on Carotid Intima-media Thickness and the Biomarkers of Atherosclerosis Compared with Insulin in Patients with Type 2 Diabetes |
|
|
| Not yet recruiting | 4 | 66 | | Exenatide ;insulin | Beijing Hospital, Ministry of Health; Beijing Hospital, Ministry of Health, AstraZeneca Investment (China) Co., Ltd | Type 2 diabetes | | | | |
ChiCTR-IPR-15005975: Intensive Lifestyle Interference for Targeted Body Weight Couple with Different Pharmacal Program in Type 2 Diabetic Patients |
|
|
| Recruiting | 4 | 147 | | Exenatide ;Humalog Mix 25 ;OAH | Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University, AstraZeneca, self-fund | Type 2 Diabetic mellitus | | | | |
ChiCTR-IPR-17010825: GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM |
|
|
| Recruiting | 4 | 152 | | Metformin or metformin + sulfonylurea ;Exenatide | Department of Endocrinology, Xinqiao Hospital of Chongqing City; Xinqiao Hospital, Clinical research project of the Second Affiliated Hospital of Third Military Medical University (yclkt-201420) | overweight and obese patients with T2DM | | | | |
ChiCTR1800015658: Effect of Exenatide on Carotid Intima-media Thickness and the Biomarkers of Atherosclerosis Compared with Insulin in Patients with Type 2 Diabetes |
|
|
| Recruiting | 4 | 66 | | Exenatide 10ugBid ;Aspart 30 insulin | Beijing Hospital; Beijing Hospital, AstraZeneca Investment (China) Co., Ltd. | Atherosclerosis | | | | |
ChiCTR-IIR-16008084: Effects of different treatment (metformin, spironolactone, GLP-1 receptor agonist. etc) on clinical and endocrine features and the levels of adipocytokine in patients with polycystic ovary syndrome. |
|
|
| Recruiting | 4 | 150 | | lifestyle counselling and exenatide | The third affiliated hospital of Guangzhou Medical University; The third affiliated hospital of Guangzhou Medical University, The National Natural Science Foundation of China | polycystic ovarian syndrome | | | | |
EEFDD, ChiCTR-IPR-14005568: Effects of exenatide on fat deposition in type 2 diabetic patients with BMI less than 25 kg/m2 but visceral obesity |
|
|
| Not yet recruiting | 4 | 98 | | Treatment of exenatide ;Humalog Mix 25 | Affiliated Hospital of Nantong University; Endocrinology Department, Affiliated Hospital of Nantong University, AstraZeneca Investment (China) Co., Ltd | type 2 diabetes | | | | |
ChiCTR1900020516: A comparative study of outcomes of pregnancy and delivery in overweight/obese patients with PCOS treated with exenatide or metformin |
|
|
| Recruiting | 4 | 160 | | lifestyle counselling and exenatide ;lifestyle counselling and metformin | The third affiliated hospital of Guangzhou Medical University; The third affiliated hospital of Guangzhou Medical University, The National Natural Science Foundation of China | polycystic ovarian syndrome | | | | |
ChiCTR2100041813: Compare the effects of Metformin and Exenatide on pregnancy rate and outcomes in overweight or obese PCOS women |
|
|
| Completed | 4 | 160 | | metformin and lifestyle intervention ;exenatide and lifestyle intervention | The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University, Endocrinology characteristics disciplines of internal medicine in the Third Affiliated Hospital of Guangzhou Medical University | Polycystic ovarian syndrome | | | | |
ChiCTR1900026430: Effect of Exenatide on paroxysmal atrial fibrillation with type 2 diabetes mellitus: a single-center, randomized, double-blind, controlled trial |
|
|
| Not yet recruiting | 4 | 60 | | Amiodarone first, then Exenatide; Amiodarone first, then Placebo (normal saline) | Jiangsu Province Hospital on Integration of Chinese and Western Medicine; Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Spontaneous | paroxysmal atrial fibrillation with type 2 diabetes mellitus | | | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
COCONUT, NCT04307797: Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes |
|
|
| Completed | 4 | 10 | Europe | 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Byetta, Glucagon 12.5ng/kg/min and 0.9% saline, Glucagon 12.5ng/kg/min | Cambridge University Hospitals NHS Foundation Trust, Antaros Medical | Type 2 Diabetes, Obesity | 10/22 | 10/22 | | |
NCT04897802: Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) |
|
|
| Recruiting | 4 | 52 | Europe | Experimental: GLP1-RA (exenatide) administration, exenatide administration, Control: Placebo administration, placebo administration (sodium chloride) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Instituto de Salud Carlos III | Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism, Psychological Disorder, Social Isolation, Hypothalamic Diseases, Pituitary Diseases, Oxytocin Deficiency | 04/24 | 12/24 | | |
NCT01107717: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM |
|
|
| Completed | 4 | 318 | US | metformin\pioglitazone\exenatide, metformin, glyburide and glargine | The University of Texas Health Science Center at San Antonio, American Diabetes Association, Amylin Pharmaceuticals, LLC., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes | 02/23 | 02/23 | | |
|
NCT05482789: Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes |
|
|
| Recruiting | 4 | 13 | US | Exenatide | Maisa N. Feghali, MD | Gestational Diabetes | 12/24 | 12/24 | | |
NCT00923715: Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia |
|
|
| Enrolling by invitation | 3 | 63 | US | Insulin, Insulin and Exenatide, Insulin and Pramlintide | Baylor College of Medicine, Albert Einstein College of Medicine of Yeshiva University | Diabetes Mellitus, Type 1 | 12/11 | 05/12 | | |
ChiCTR-IPR-15006558: A randomized, double-blinded, postive-controlled, multicentered, 16-week study, assessing the effecacy and safeness of exenatide in type 2 diabetes with metformin/secretagogues alone or both |
|
|
| Completed | 3 | 240 | | exenatide ;Byetta | Peking University Third Hospital; Level of the institution：, Qinghai Chenfei Pharmaceutical Corparation, LTD | Type 2 diabetes mellitus | | | | |
2013-004755-21: Assessing efficacy and safety of exenatide in the treatment of hypothalamic obesity Evaluer l’efficacité et la tolérance du traitement par exénatide dans l’obésité hypothalamique. |
|
|
| Ongoing | 3 | 50 | Europe | Solution for injection in pre-filled pen, BYETTA | CHU de Bordeaux, Ministry of Health | Hypothalamic obesity after craniopharyngioma therapy. Obésité hypothalamique de l’adulte secondaire au traitement du craniopharyngiome., Hypothalamic obesity. Obésité hypothalamique, Body processes [G] - Metabolic Phenomena [G03] | | | | |
NCT00679042: Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol |
|
|
| Active, not recruiting | 3 | 21 | US | Islets of Langerhans transplantation, Islets of Langerhan (Islets), Basiliximab (Simulect®), Tacrolimus (Prograf®), Sirolimus (Rapamune®), Etanercept(Enbrel®), Exenatide (Byetta®) | CellTrans Inc. | Type 1 Diabetes Mellitus | 07/17 | 06/26 | | |
| Recruiting | 3 | 270 | RoW | Exendin-4 Fc fusion protein injection, JY09(1.2mg), JY09(2.4mg), Placebo, Injection mimetic | Beijing Dongfang Biotech Co., Ltd. | Type 2 Diabetes Mellitus | 04/25 | 12/25 | | |
DFBT-JY09-DM-302, NCT06257966: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin |
|
|
| Recruiting | 3 | 600 | RoW | Exendin-4 Fc fusion protein injection(1.2mg）, JY09(1.2mg), Exendin-4 Fc fusion protein injection（2.4mg）, JY09(2.4mg), Dulaglutide, Metformin | Beijing Dongfang Biotech Co., Ltd. | Type2 Diabetes Mellitus | 04/25 | 12/25 | | |
| Completed | 2/3 | 92 | US | Byetta 5Mcg Pen Injection, Exenatide | University of Colorado, Denver, National Center for Advancing Translational Sciences (NCATS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity | 12/22 | 12/22 | | |
ACTRN12609000983202: Exenatide in acute ischemic stroke - effect on cerebral inflammation and glucose homeostasis |
|
|
| Not yet recruiting | 2 | 10 | | | Monash university eastern clinical research unit, Monash university eastern clinical research unit | Acute ischemic stroke | | | | |
| Not yet recruiting | 2 | 50 | | | Monash University eastern clinical research unit, Monash University eastern clinical research unit, Eastern Health Research Grant 2012 | Acute ischemic stroke, Hyperglycemia | | | | |
2011-002780-16: A study of efficacy and safety of the glucose lowering drug Exenatide on patients with suspected acute stroke and hyperglycemia |
|
|
| Ongoing | 2 | 100 | Europe | Byetta, Novorapid, A10AB05, Solution for injection in pre-filled pen, Byetta, Novorapid | Karolinska Institutet, Karolinska institutet Södersjukhuset | Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of Byetta or standard care., Patients with hyperglycemia and symptoms of acute stroke will be randomized to either subcutaneous injection with 10ug of the glucose lowering drug Byetta or standard care against hyperglycemia., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2009-014272-21: Effect of additional treatment with exenatide in patients with an acute myocardial infarction: the EXAMI trial) |
|
|
| Ongoing | 2 | 40 | Europe | Byetta, Byetta | VU University Medical Center | Acute Myocardial Infartion to be treated with primary PCI | | | | |
2010-023179-25: Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome |
|
|
| Ongoing | 2 | 20 | Europe | Byetta, EU/1/06/362/003: 5μg (1 pen), Byetta, Byetta | Aintree University Hospital NHS Foundation Trust, UNIVERSITY OF LIVERPOOL | Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection. | | | | |
2020-004115-27: Identification and clinical relevance of oxytocin deficient status: GLP1 study Identificación y relevancia clínica de un estado deficiente de oxitocina: Estudio GLP1 |
|
|
| Ongoing | 2 | 52 | Europe | Solution for injection in pre-filled pen, Byetta | Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau, Instituto de Salud Carlos III | Hypopituitarism Hipopituitarismo, Hypopituitarism Hipopituitarismo, Diseases [C] - Hormonal diseases [C19] | | | | |
| Completed | 2 | 528 | | | Monash University Eastern Health Clinical School., NH&MRC | acute ischaemic stroke | | | | |
| Active, not recruiting | 2 | 350 | Europe, RoW | Exenatide Injection, Byetta | Neuroscience Trials Australia, National Health and Medical Research Council, Australia, Monash University | Acute Ischemic Stroke | 10/21 | 12/21 | | |
| Recruiting | 2 | 30 | Europe | Byetta, Exenatide, GLP-1 receptor analogue, GLP-1 receptor agonist, Normosaline, Isotonic saline | Christina Kruuse | Ischemic Stroke | 08/23 | 11/23 | | |
| Active, not recruiting | 2 | 60 | Europe | Exenatide, Placebo | Center for Neurology, Stockholm, Karolinska Institutet | Parkinson Disease | 10/23 | 10/23 | | |
| Terminated | 1 | 78 | US | Exenatide Injection, BYETTA, Saline injection | University of Maryland, Baltimore | Type 2 Diabetes | 11/18 | 10/22 | | |
ChiCTR1900022449: Single ascending dose safety, tolerance and pharmacokinetics/pharmacodynamics of Exendin-4 Fc fusion protein (JY09) injection in healthy subjects: a randomized, double-blinding, placebo-controlled trial |
|
|
| Completed | 1 | 41 | | Exendin-4 Fc Fusion protein injection 0.3mg ;Exendin-4 Fc Fusion protein injection 0.7mg ;Exendin-4 Fc Fusion protein injection 1.5mg ;Exendin-4 Fc Fusion protein injection 3mg ;Exendin-4 Fc Fusion protein injection 6mg | Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School; Beijing Eastren Biorech Co., Ltd., Beijing Eastren Biorech Co.,Ltd. | Type 2 Diabetes | | | | |
NCT05034783: [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients |
|
|
| Active, not recruiting | 1 | 20 | RoW | [68Ga]Ga-HBED-CC-exendin-4, [68Ga]Ga-HBED-CC-exendin-4 injection, [68Ga]Ga-NOTA-exendin-4, [68Ga]Ga-NOTA-exendin-4 injection | Peking Union Medical College Hospital | Insulinoma | 10/22 | 06/23 | | |
ChiCTR2300069894: A randomized, open, two-preparation, two-sequence, two-cycle, cross-single dose clinical study on bioequivalence of exenatide injection in humans |
|
|
| Not yet recruiting | 1 | 24 | | Inject the test preparation subcutaneously, and inject the reference preparation subcutaneously after three days of washing. ;Subcutaneously inject the reference formulation and subcutaneously inject the test formulation three days after washing. | West China Hospital, Sichuan University; West China Hospital of Sichuan University, raise independently | Patients with type 2 diabetes | | | | |
NCT06247748: Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects |
|
|
| Completed | 1 | 28 | RoW | Exendin-4 Fc fusion protein (JY09) injection, JY09, Metformin Hydrochloride tablet, Metformin, Rosuvastatin calcium tablets, Rosuvastatin, Digoxin tablet, digoxin | Beijing Dongfang Biotech Co., Ltd. | Diabetes Mellitus, Type 2, Overweight | 04/24 | 04/24 | | |
NCT04979611: The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma |
|
|
| Recruiting | 1 | 60 | RoW | 68Ga-NOTA-exendin-4 | First Affiliated Hospital of Fujian Medical University | Insulinoma | 08/25 | 08/25 | | |
| Completed | N/A | 20 | | Exenatide injection and Metformin | The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Fund from Suzhou Science & Technology Bureau (SYS201455)(SYS201534) | Diabetes mellitus | | | | |
ChiCTR-ONRC-14004356: Insulin pump intensive treatment combined with insulin and Byetta to reverse type 2 diabetes mellitus |
|
|
| Completed | N/A | 40 | | Insulin pump intensive treatment + insulin treatment for half a year ;Insulin pump intensive treatment for 2 weeks + insulin treatment for 6 months + 100% of the treatment for 6 months | Song County People's Hospital; Song County People's Hospital, from the technology bureau of Luoyang city and self-raised | type 2 diabetes mellitus | | | | |
ChiCTR-INR-16008242: Therapeutic effect of the Exenatide in the treatment of polycystic ovary syndrome |
|
|
| Not yet recruiting | N/A | 60 | | Exenatide+metformin ;metformin | Shengjing Hospital affiliated to China Medical University; shengjing hospital, self-financing | polycystic ovary syndrome | | | | |
| Completed | N/A | 20 | Europe | Ga-68-NODAGA-exendin-4 PET/CT | Radboud University Medical Center | Diabetes Mellitus, Type 2 | 04/24 | 04/24 | | |
ChiCTR2100047491: Bone morphogenetic protein-9 is involved in insulin resistance in polycystic ovary syndrome |
|
|
| Completed | N/A | 30 | | patients received interventional treatment with exenatide (EX) for 3 months. | Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University, Regional Science Foundation Project | Polycystic ovary syndrome | | | | |
GLP1R-T2D, NCT04733508: Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes |
|
|
| Recruiting | N/A | 28 | Europe | 111In-DTPA-exendin-4, IRDye800CW-exendin-4 | Radboud University, University of Coimbra | Diabetes Mellitus, Diabetes Mellitus, Type 2 | 06/22 | 12/22 | | |
| Completed | N/A | 26 | Europe | Saline 0.9%, Placebo, Glucagon (25ng/kg/min), Glucagon, Glucagon (50ng/kg/min), Exenatide | Cambridge University Hospitals NHS Foundation Trust | Cardiovascular Diseases | 11/21 | 11/21 | | |
ChiCTR2100045343: Bone morphogenetic protein-9 is involved in insulin resistance in polycystic ovary syndrome |
|
|
| Recruiting | N/A | 60 | | Exenatide intervention therapy ;None | Affiliated Hospital of Zunyi Medical University; Zunyi Medical University, Regional Science Foundation Project | Polycystic ovary syndrome | | | | |
| Active, not recruiting | N/A | 1400 | Europe | Byetta (Lilly, Exenatide), GLP-1 agonist, Conoxia (AGA, oxygen), Oxygen, 20% Human Albumin, Albumin | Rigshospitalet, Denmark | Coronary Disease, Shock, Cardiogenic, Renal Failure, Stroke, Brain Injury, Aortic Valve Disease | 09/24 | 09/24 | | |
NCT02244164: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments. |
|
|
| Terminated | N/A | 5 | Europe | Incretinomimetics, - exenatide (Byetta®), - liraglutide (Victoza®), - lixisenatide (Lyxumia®), - exenatide extended-release (Bydureon®)., DPP-4 inhibitors, - sitagliptine (Januvia®), - vildagliptine (Galvus®), - saxagliptine (Onglyza®), - linagliptine (Trajenta®). | Erasme University Hospital | Type 2 Diabetes, Incretinomimetics, Pancreas | 02/23 | 02/23 | | |
| Completed | N/A | 29 | Europe | Exenatide, Day 1 Exenatide; Day 2 : 0.9% saline solution, 0.9% saline solution, Day 1 : 0.9% saline solution, Day 2 Exenatide | University Hospital, Basel, Switzerland, Gottfried und Julia Bangerter-Rhyner-Stiftung | Endogenous Hyperinsulinism | 04/24 | 04/24 | | |
XYFY2023-KL479-01, NCT06256419: Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM |
|
|
| Recruiting | N/A | 300 | RoW | GLP-1 receptor agonist, responders group and nonresponders group | The Affiliated Hospital of Xuzhou Medical University | Type 2 Diabetes Mellitus, Susceptibility, Genetic | 01/28 | 01/28 | | |
| Recruiting | N/A | 270000 | US | SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA) | Kaiser Permanente, Geisinger Clinic, Henry Ford Health System, HealthPartners Institute, Patient-Centered Outcomes Research Institute | Type 2 Diabetes Mellitus, Cardiovascular Diseases | 12/24 | 08/25 | | |
CER-4-T2D, NCT05220917: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study |
|
|
| Active, not recruiting | N/A | 781430 | US | SGLT2 inhibitor, CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE, DPP-4 inhibitor, ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, GLP-1RA, INSULIN DEGLUDEC/LIRAGLUTIDE*, INSULIN GLARGINE, HUMAN RECOMBINANT ANALOG/LIXISENATIDE*, LIXISENATIDE, LIRAGLUTIDE, DULAGLUTIDE, SEMAGLUTIDE, ALBIGLUTIDE, EXENATIDE MICROSPHERES, EXENATIDE, 2nd generation SU, PIOGLITAZONE HCL/GLIMEPIRIDE, ROSIGLITAZONE MALEATE/GLIMEPIRIDE, GLIPIZIDE/METFORMIN HCL, GLYBURIDE,MICRONIZED, GLYBURIDE/METFORMIN HCL, GLIMEPIRIDE, GLYBURIDE, GLIPIZIDE | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute, VA Boston Healthcare System, McGill University | Cardiovascular Events, Type2 Diabetes, Renal Disease | 07/24 | 07/24 | | |
ChiCTR2300074467: The Comparative Study of [68Ga]-Exendin-4 and [68Ga]-DOTANOC PET/CT for Imaging of Insulinoma |
|
|
| Not yet recruiting | N/A | | | | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, expenditure of department | Insulinoma | | | | |
| Trulicity (dulaglutide) / Eli Lilly |
2018-002162-38: A study comparing the effect of Dulaglutide (TRULICITY®) add-on to dietary reinforcement versus dietary reinforcement alone in patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis Une étude comparant l'effet du Dulaglutide (TRULICITY®) en plus du renforcement diététique versus le renforcement diététique seul chez des patients diabétiques de type 2 et porteurs d'une stéatohépatite non alcoolique (NASH). |
|
|
| Not yet recruiting | 4 | 120 | Europe | Solution for injection in pre-filled pen, TRULICITY | CHRU de Nancy, LILLY France | Patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis (NASH). Patients diabétiques de type 2 atteints d'une stéatohépatite non alcoolique (NASH)., Patients with type 2 diabetes and carriers of a non-alcoholic steatohepatitis (NASH). Patients diabétiques de type 2 atteints d'une stéatohépatite non alcoolique (NASH)., Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-003844-57: Comparison of injection site pain experience for semaglutide and dulaglutide sc |
|
|
| Not yet recruiting | 4 | 104 | Europe | Solution for injection, Ozempic, Trulicity | Novo Nordisk A/S, Novo Nordisk A/S | Healthy volunteers(Diabetes Mellitus, Type 2)(Overweight)(Obesity), Healthy volunteers(Type 2 diabetes)(Overweight)(Obesity), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04893148: Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 40 | RoW | IGlarLixi, Dulaglutide, Insulin Glargine | Chungbuk National University Hospital | Type 2 Diabetes Mellitus, Glucose, High Blood | 12/21 | 12/22 | | |
| Not yet recruiting | 4 | 93 | Europe | dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring | Central Hospital, Nancy, France, Eli Lilly and Company | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | 09/23 | 03/24 | | |
NCT04387201: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response |
|
|
| Active, not recruiting | 4 | 23 | US | Cyanocobalamin, Vitamin B12, Dulaglutide, Trulicity | The University of Texas Health Science Center, Houston | Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity | 10/23 | 10/24 | | |
NCT03743025: Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients |
|
|
| Terminated | 4 | 28 | US | Dulaglutide Injection, Trulicity, Saline Injection, Sodium Chloride Injection | Emory University, National Institute of General Medical Sciences (NIGMS) | Stress Hyperglycemia | 05/23 | 05/23 | | |
NCT05005741: The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity. |
|
|
| Recruiting | 4 | 120 | RoW | Beinaglutide, GLP-1 receptor agonist, Dulaglutide, Trulicity | Second Xiangya Hospital of Central South University, Guangdong Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Henan University of Science and Technology | Diabetes Mellitus, Type 2, Overweight or Obesity | 12/23 | 12/23 | | |
NCT05659537: A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India |
|
|
| Completed | 4 | 200 | RoW | Dulaglutide, LY2189265 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 01/24 | 01/24 | | |
GLUMINS, NCT06324461: GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery |
|
|
| Recruiting | 4 | 372 | RoW | Dulaglutide 0.75mg subcutaneous injection, Trulicity 0.75mg subcutaneous injection | The University of Hong Kong, Research Grants Council, Hong Kong | Myocardial Injury | 12/26 | 12/27 | | |
NCT05218915: Basal Plus GLP1-ra on Glycemic Variability in CKD |
|
|
| Recruiting | 4 | 100 | RoW | Dulaglutide, Insulin Degludec, Continuous glucose monitor | Elaine Chow | Diabetes Mellitus, Diabetic Kidney Disease | 06/24 | 01/25 | | |
NCT05140694: Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D |
|
|
| Not yet recruiting | 4 | 135 | NA | Empagliflozin, Jardiance, Dulaglutide, Trulicity, Empagliflozin and Dulaglutide, Jardiance and Trulicity | Seoul National University Bundang Hospital | Metabolic-associated Fatty Liver Disease, Type 2 Diabetes | 06/24 | 12/25 | | |
| Completed | 4 | 282 | Europe, US, RoW | Tirzepatide, LY3298176, Dulaglutide, LY2189265 | Eli Lilly and Company | Type 2 Diabetes | 07/24 | 08/24 | | |
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh |
|
|
| Not yet recruiting | 4 | 938 | RoW | Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd. | Type2diabetes | 04/25 | 06/25 | | |
NCT04862234: Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients |
|
|
| Recruiting | 4 | 80 | US | Dulaglutide, Trulicity, Placebo, Continuous glucose monitor (CGM), blinded, FreeStyle Libre Pro | Emory University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hyperglycemia Stress | 05/25 | 05/25 | | |
| Recruiting | 4 | 6000 | US | SGLT2 inhibitor, GLP-1 receptor agonist | Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute | Type2Diabetes, ASCVD | 03/29 | 03/29 | | |
| Completed | 3 | 591 | Japan | Dulaglutide, LY2189265, Oral antihyperglycemics | Eli Lilly and Company | Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents, Type 2 Diabetes Mellitus (T2DM) | 10/22 | 04/23 | | |
NCT06235086: Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 618 | RoW | TG103, Dulaglutide | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 03/26 | 11/26 | | |
| Completed | 3 | 731 | RoW | dulaglutide, IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes | 01/24 | 04/24 | | |
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
|
|
| Active, not recruiting | 3 | 623 | RoW | Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
| Active, not recruiting | 3 | 13299 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Dulaglutide, LY2189265 | Eli Lilly and Company | Type 2 Diabetes Mellitus | 06/25 | 06/25 | | |
2008-005128-10: Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions |
|
|
| | 2 | 40 | Europe | LY2189265, LY2189265, | Eli Lilly and Company - Indianapolis, Lilly S.A. | Type II Diabetes Mellitus | | | | |
2019-003001-94: Use of GLP-1 analogs in the treatment of multiple sclerosis Použitie GLP-1 analógov v terapii sklerózy multiplex |
|
|
| Ongoing | 2 | 50 | Europe | Trulicity 0,75 mg injekčný roztok naplnený v injekčnom pere, Solution for injection in pre-filled pen, Trulicity 0,75 mg injekčný roztok naplnený v injekčnom pere. | Lekárska fakulta UK Bratislava, Ministry of Health | Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurodegeneration, and manifested by insulin resistance in both peripheral tissues and the CNS. Naša hypotéza je, že pacienti so SM majú poruchu energetického metabolizmu v neurónoch a gliálnych bunkách CNS, čo prispieva k vzniku a progresii demyelinizačných ložísk a k neurodegenerácii, a čo sa prejavuje inzulínovou rezistenciou tak v periférnych tkanivách ako aj v CNS., Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, manifested by insulin resistance in both peripheral tissues and the CNS. Naša hypotéza je, že pacienti so SM majú poruchu energetického metabolizmu v neurónoch a gliálnych bunkách CNS, čo sa prejavuje inzulínovou rezistenciou tak v periférnych tkanivách ako aj v CNS., Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-000393-29: Dulaglutide And Insulin MicrosecretiON in type I Diabetes - DIAMOND |
|
|
| Not yet recruiting | 2 | 72 | Europe | Solution for injection, TRULICITY | Hospices Civils de Lyon, Ministry of Health, Lilly | Adult patients with Type 1 Diabètes (T1D)> 4years, Adult patients with Type 1 Diabetes > 4years, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-002806-29: Effect of LY3502970 Versus Placebo and Dulaglutide in Participants with Type 2 Diabetes Mellitus |
|
|
| Ongoing | 2 | 370 | Europe | Dulaglutide, LY3502970, Capsule, Solution for injection in pre-filled pen, Trulicity | Eli Lilly and Company, Eli Lilly and Company | Type 2 diabetes mellitus, Type 2 diabetes mellitus, Diseases [C] - Hormonal diseases [C19] | | | | |
NCT04965506: A Study of IBI362 in Chinese Patients With Type 2 Diabetes |
|
|
| Completed | 2 | 252 | RoW | IBI362, placebo, Dulaglutide | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes | 04/22 | 06/22 | | |
NCT05348122: A Study of TG103 Injection in Type 2 Diabetes Subjects |
|
|
| Not yet recruiting | 2 | 240 | RoW | TG103,Q2W, TG103 injection, subcutaneous injection,Q2W, TG103,QW, TG103 injection, subcutaneous injection,QW, Placebo,Q2W, Placebo, subcutaneous injection,Q2W, Placebo,QW, Placebo, subcutaneous injection,QW, Dulaglutide,QW, Dulaglutide,subcutaneous injection,QW | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 11/23 | 11/23 | | |
NCT06148649: Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 2 | 225 | RoW | HEC88473, Placebo, Dulaglutide | Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Type 2 Diabetes | 09/24 | 09/24 | | |
| Completed | 2 | 7 | US | dulaglutide injection | Vanderbilt University Medical Center, Nashville VA Medical Center | Chronic Kidney Diseases | 05/24 | 08/24 | | |
NCT04731272: GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance |
|
|
| Recruiting | 2 | 30 | US | Dulaglutide 0.75Mg/0.5Ml Inj Pen | University of Pennsylvania, Children's Hospital of Philadelphia | Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes | 06/26 | 06/27 | | |
| Recruiting | 2 | 64 | US | Dulaglutide, Placebo, exercise training | University of Virginia | Diabetes Mellitus, Type 1, Endothelial Dysfunction | 06/27 | 06/27 | | |
ChiCTR2200066519: A randomized, open-label, single-dose, parallel-controlled phase I clinical trial to compare the pharmacokinetic profiles, safety, tolerability, and immunogenicity of LY05008 (dulaglutide injection) and TRULICITY in healthy Chinese male subjects |
|
|
| Not yet recruiting | 1 | 106 | | LY05008 (dosage 1) ;TRULICITY (dosage 2) ;LY05008 (dosage 3) ;TRULICITY (dosage 4) | The Second Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Shandong Boan Biotechnology Co., LTD | Type 2 diabetes in adults | | | | |
NCT05516966: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 64 | RoW | HRS9531, Placebo, Dulaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
NCT05377333: A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes |
|
|
| Completed | 1 | 94 | US | LY3457263, Placebo, Dulaglutide, LY2189265 | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 11/23 | 11/23 | | |
NCT05407961: A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 90 | Europe | LY3532226, Placebo, Dulaglutide, Trulicity | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 01/24 | 01/24 | | |
| Not yet recruiting | N/A | 95 | | | Auckland City Hospital, Auckland Hospitals Research and Endowment Fund (AHREF), | End stage kidney disease, Diabetes | | | | |
NCT06611904: The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria |
|
|
| Active, not recruiting | N/A | 60 | Europe | Dulaglutide, DPP-4 Inhibitors | Attikon Hospital | Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness | 02/22 | 12/24 | | |
| Completed | N/A | 78 | Europe | Empagliflozin, E, Dulaglutide, D, Control Rx, C | National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, Hippocration General Hospital | Non-Alcoholic Fatty Liver Disease, Liver Steatosis | 05/21 | 05/21 | | |
NCT06182891: Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy |
|
|
| Completed | N/A | 300 | RoW | Dulaglutide Injection, Other hypoglycemic agents not including GLP-1 receptor agonists | The Affiliated Hospital of Xuzhou Medical University | Type 2 Diabetic Nephropathy | 06/23 | 10/23 | | |
